PolyPeptide publishes invitation to the annual General Meeting 2026
Baar, 17 March 2026 – PolyPeptide Group AG (SIX: PPGN), a specialized global CDMO for peptide-based active pharmaceutical ingredients, published today the invitation to the fifth annual General Meeting, which will take place on 8 April 2026 at the Chollerhalle in Zug.
At PolyPeptide Group AG’s (the “Company”) fifth annual General Meeting, which will take place on 8 April 2026 at the Chollerhalle in Zug (the “AGM 2026”), all six current members of the Board of Directors will stand for re-election. Peter Wilden is proposed for re-election as Chair of the Board of Directors, and Philippe Weber and Peter Wilden as members of the Remuneration and Nomination Committee.
Further proposals include, among others, the re-election of the Statutory Auditors and the Independent Proxy as well as the approval of the maximum aggregate amount of compensation of the Board of Directors and Executive Committee. The shareholders will also be asked to approve the Management Report, Statutory Financial Statements, Consolidated Financial Statements and the report on non-financial matters, in each case, for the financial year 2025 as well as the Remuneration Report 2025 in a separate consultative vote.
The invitation to the AGM 2026 with the detailed proposals and explanations can be found here